UNSPSC 51292922: Imipramine pamoate

This classification denotes a tricyclic antidepressant with the molecular formula C23H16O6.2C19H24N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MC34P30298. European Medicines Agency schedules imipramine pamoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02643MIG. The term imipramine embonate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule imipramine pamoate under HS 29339990.

As of Q4 2014, IMIPRAMINE PAMOATE remains US FDA's Preferred Term for this commodity. Imipramine pamoate bears US NLM identifiers UMLS ID C0304368 and NCI Concept Code C61788. SMILES: CN(C)CCCN1C2CCCCC2CCC3C1CCCC3.CN(C)CCCN1C2CCCCC2CCC3C1CCCC3.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O.

UNSPSC 51292922 Imipramine pamoate is a Commodity code that encompasses pharmaceutical active ingredients and finished-drug products procured by state and local health agencies, but recent state and local solicitations tagged under this code show minimal alignment with imipramine pamoate specifically. The three most recent opportunities—a Seminole County naloxone and drug deactivation system procurement, a Texas HHS direct-to-manufacturer prescription program RFI, and a Minnesota multistate cooperative purchasing alliance RFP for generic multi-source pharmaceuticals and OTC products—are broad pharmaceutical and medical-supply acquisitions rather than targeted procurement of imipramine pamoate by name. State procurement offices, county health departments, and cooperative purchasing alliances are the primary issuing bodies, but the actual buying under this code appears driven by multi-product formulary management and supply-chain aggregation rather than single-active-ingredient specifications.

Activity is dispersed across Florida, Texas, and Minnesota through state health agencies and county public-health bodies. The Seminole County, Florida IFB (solicitation IFB60459723LAS, response due July 26, 2023) sought naloxone and drug deactivation systems on an annual basis with quarterly deliveries; the Texas Health and Human Services Commission RFI (HHS0017013, posted April 3, 2026) explored direct-to-manufacturer prescription fulfillment capabilities; and the Minnesota Department of Administration's MMCAP RFP (S1070000015802, due March 26, 2026) aggregated generic pharmaceuticals and OTC products across multiple state and local jurisdictions through three authorized wholesalers with two-year contract terms. None of these solicitations target imipramine pamoate as a line item, suggesting the code may carry limited relevance to current state and local procurement activity or that buyers tag pharmaceutical acquisitions to higher-tier family or class codes that capture broader drug categories rather than individual active ingredients.